<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1170">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04410562</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001587-29</org_study_id>
    <nct_id>NCT04410562</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum</brief_title>
  <acronym>COVID-Preg</acronym>
  <official_title>Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Torrejon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de investigación HM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Infanta Leonor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Fundación Alcorcón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de Segovia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català de la Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barcelona Institute for Global Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which&#xD;
      factors may influence obstetrical disease and outcomes, including the timing of maternal&#xD;
      viral exposure by gestational age, the effects of parity, age, host immune responses,&#xD;
      coexisting medical and obstetrical conditions and the effects of treatment regimens. While&#xD;
      further information is gathered, based on the existing evidence from other infections causing&#xD;
      pneumonia, pregnant women should be considered to be at high risk for developing severe&#xD;
      infection during the current COVID-19 epidemic. Results from clinical trials with HCQ in&#xD;
      nonpregnant adults may not be directly extrapolated to pregnant women given the special&#xD;
      features of the pregnancy status. Thus, clinical research is urgently needed to improve the&#xD;
      care and reduce the risk of poor pregnancy outcomes of women in this and in future epidemics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blinded, placebo-controlled multicenter clinical trial including&#xD;
      714 pregnant women (200 SARS-CoV-2 infected -100 symptomatic with mild disease and 100&#xD;
      asymptomatic- pregnant women and 514 SARS-CoV-2 uninfected pregnant women who are contacts&#xD;
      with a SARS-CoV-2 case) with the main objectives of assessing the safety and efficacy of oral&#xD;
      hydroxychloroquine (HCQ) in reducing maternal viral shedding by PCR, and preventing incident&#xD;
      SARS-CoV-2 infection and disease severity. Pregnant women undergoing antenatal follow up at&#xD;
      five maternity hospitals, presenting at least one sign and/or one mild suggestive symptoms&#xD;
      and a positive SARS-CoV-2 PCR test, or who are contacts of a suspected or confirmed case,&#xD;
      will be recruited and randomized 1:1 to receive HCQ orally (400 mg/day for 3 days, followed&#xD;
      by 200 mg/day for 11 days) or placebo. Women will be followed up for the duration of the&#xD;
      intervention. One week after intervention completion, a SARS-CoV-2 PCR test will be repeated.&#xD;
      At delivery, the pregnancy outcome will be registered, and a cord blood sample will be&#xD;
      collected to measure for IgG and IgM of SARS-CoV-2. A neonatal nasopharyngeal aspirate will&#xD;
      be collected to perform PCR SARS-CoV-2 testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded, placebo-controlled multicentre clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of PCR confirmed cases among pregnant women</measure>
    <time_frame>21 days after intervention</time_frame>
    <description>Number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 disease during pregnancy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19-related admissions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause admissions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause outpatient attendances</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of symptoms-signs of COVID-19</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gestational diabetes</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SARS-CoV-2 infections during pregnancy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of intrauterine growth restriction</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal mortality rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neonates with clinical signs/symptoms of COVID-19</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of low birth weight (&lt;10th centile according to local standards)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of preterm birth (&lt;37 weeks of gestational age)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of embryo and foetal losses (miscarriages and stillbirths)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of congenital malformations</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse perinatal outcome</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">714</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>COVID</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Dolquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting with fever (≥37.5ºC) and/or one mild symptom suggestive of COVID-19 disease&#xD;
             (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, taste&#xD;
             disorder, headache) OR contact of a SARS-CoV-2 confirmed or suspected case in the past&#xD;
             14 days&#xD;
&#xD;
          -  More than 12 weeks of gestation (dated by ultrasonography)&#xD;
&#xD;
          -  Agreement to deliver in the study hospitals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to HCQ or other 4-aminoquinoline compounds&#xD;
&#xD;
          -  History of retinopathy of any aetiology&#xD;
&#xD;
          -  Concomitant use of digoxin, cyclosporine, cimetidine&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Clinical history of cardiac pathology including known long QT syndrome&#xD;
&#xD;
          -  Unable to cooperate with the requirements of the study&#xD;
&#xD;
          -  Participating in other intervention studies&#xD;
&#xD;
          -  Delivery onset (characterized by painful uterine contractions and variable changes of&#xD;
             the cervix, including some degree of effacement and slower progression of dilatation&#xD;
             up to 5 cm for first and subsequent labours)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clara Menéndez, MD.PhD</last_name>
    <phone>+34 932275400</phone>
    <phone_ext>3166</phone_ext>
    <email>clara.menendez@isglobal.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raquel González, MD.PhD</last_name>
    <phone>+34 932275400</phone>
    <phone_ext>4144</phone_ext>
    <email>raquel.gonzalez@isglobal.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <state>Cartilla Y León</state>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paloma Toro, MD</last_name>
      <email>ptorop@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Ferriols, MD</last_name>
      <email>EFerriols@parcdesalutmar.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Gonce, MD, PhD</last_name>
      <phone>+34 93 227 5400</phone>
      <email>AGONCE@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Sant Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Llurba, MD, PhD</last_name>
      <phone>93 291 90 00</phone>
      <email>Elisa.Llurba@uab.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Catalunya</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edurne Mazarico, MD, PhD</last_name>
      <email>emazarico@sjdhospitalbarcelona.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Adiego, MD</last_name>
      <email>mbadiego@fhalcorcon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HM Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Rodríguez Zambrano, MD</last_name>
      <phone>902 08 98 00</phone>
      <email>mrodzambrano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrejón</name>
      <address>
        <city>Torrejón De Ardoz</city>
        <state>Madrid</state>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Mar Gil, MD, PhD</last_name>
      <phone>916 26 26 26</phone>
      <email>mgil@torrejonsalud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Sáez, MD</last_name>
      <email>emaria.saezce@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>covid-19</keyword>
  <keyword>coronavirus</keyword>
  <keyword>hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>It would be shared at time of publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>By the end of study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

